Inflation Blinked.
Oil Struck Back.
Week of July 20 — WING · IQV · OLLI
June CPI cooled hard — collapsing July hike odds to ~15% — just as the Iran ceasefire broke and oil rebounded ~9%. Into that whipsaw, three non-tech setups: two consumer names and a quality healthcare compounder.
Inflation cooled — then the Iran ceasefire broke
On July 14, June CPI came in well below expectations: headline prices fell 0.4% MoM — the largest single-month drop since April 2020 — pulling annual inflation to 3.5% (under the 3.8% consensus), with a 9.7% slide in gasoline. July rate-hike odds collapsed from ~40% to ~15%, the July 28–29 FOMC is now expected to hold, and risk assets rallied.
The catch: the U.S.–Iran ceasefire collapsed on July 8, and oil rebounded ~9% on renewed Hormuz tensions — threatening to reverse June's energy-driven disinflation. Chair Warsh stayed pointedly cautious against reading the soft print as "mission accomplished." A relief rally, meeting a fresh energy risk.
The crosscurrent lands on the consumer. Cooling inflation and cheaper gasoline are real relief for the stretched, lower-income shopper — a tailwind for WING and OLLI — but a renewed oil spike could snatch it back.
So the list stays deliberately outside mega-cap tech: a beaten-down growth restaurant, a deep-value discounter, and — as ballast — a high-quality healthcare-data compounder riding AI into clinical trials.
The beaten-down growth franchise
WING carries the eye-catching number: a 135.7% annualized return, far the highest of the three, with an 81.82% frequency and 80% win rate. The 4.49 profit factor is modest — the magnitude of this window is what stands out.
Wingstop is an asset-light, highly franchised brand mid-expansion: Q1 added 97 net new locations (~17% unit growth), digital hit 72.5% of sales, adjusted EPS rose 19% to $1.18, and it declared a dividend plus a $300M buyback. The catch is traffic — domestic same-store sales fell 8.7% on weather, gas prices, and lower-income guest pressure. Management expects a return to positive SSS in 2H.
The macro helps: cooling inflation and a ~10% drop in gasoline are exactly the relief WING's stretched customer needs into a 2H recovery. Add elevated short interest and a stock that popped 15% to ~$173 (still well below ~$234–$237 targets), and there's real squeeze potential into the print. Offset: a ~36× forward multiple and soft Q2 sales.
Wednesday, July 29, 2026 (before open, confirmed). Watch same-store-sales trend, unit growth, and any short squeeze.
A premium-multiple consumer-discretionary name — helped by last week's lower yields and cooling inflation, but exposed to the lower-income consumer and any renewed energy spike. Traffic is the swing factor.
By far the highest annualized return on the list, a fast-growing franchise beaten down on soft same-store sales with squeeze potential into a July 29 print. Cooling inflation is a real tailwind for its customer; the risks are Q2 traffic, a premium multiple, and a renewed oil spike.
The quality healthcare-AI compounder
IQV is the steady anchor, owning two categories: the best profit factor at 11.51 and the best annual win rate at 83.33%, with an 84.62% frequency. Its 75% annualized return is the most modest — the trade-off for being the lowest-drama name.
IQVIA is the dominant force in pharmaceutical data and clinical research — a CRO plus a healthcare-intelligence and analytics powerhouse. It's remarkably consistent: it has beaten estimates each of its last four quarters (and ~49 of 55 as a public company), with Q1 revenue ~$4.15B and the stock up ~26% over the past year.
A clean, on-theme catalyst away from mega-cap tech: AI in clinical trials. On July 1, IQV jumped ~6% after Baird upgraded its target to $249 and tagged it a "Bullish Fresh Pick," arguing IQVIA sits on the front lines of AI transforming the trial market. Average target ~$230 vs a ~$209 price; Strong Buy consensus. Quality growth on sale.
Expected Tuesday, July 28, 2026 (est.). Q2 EPS consensus ~$2.74 (+8% YoY) — watch bookings, book-to-bill, and AI-in-trials commentary.
The defensive-growth ballast: a recurring-revenue healthcare-data business far more insulated from the consumer and the Fed than the other two. Its one sensitivity is biotech R&D funding — cushioned by the AI-trials tailwind and its consistency.
Best profit factor and win rate on the list, a consistent-beating healthcare-data compounder with a genuine AI-in-clinical-trials tailwind and a fresh Baird upgrade. The quality anchor — watch biotech-funding sensitivity into a ~July 28 print.
The deep contrarian value setup
OLLI is the deep-value name, and it demands honesty. The profile is respectable — 81.82% frequency, 79.68% annualized — but the 70% win rate is the lowest here, a reminder the appeal is as much price as stats.
Ollie's is a deep-discount "treasure-hunt" closeout retailer, and the business is doing well: Q1 net sales rose 14%, adjusted EPS beat, margins expanded, management raised full-year guidance, and it plans ~75 new stores. Yet the stock trades near $74 — close to its 52-week low (~$71) — down ~13% since early June.
The disconnect is stark: the average analyst target sits near $120, implying ~60% upside, with 13 Buys and none to sell. Closeout retail is counter-cyclical — it thrives when consumers trade down. The counterweight: momentum is poor (technicals read "strong sell"), and targets are being trimmed (Truist just cut to $80). A value setup with real falling-knife risk.
Expected Thursday, August 27, 2026 (est.) — the furthest out. The seasonal window runs well ahead of the catalyst.
Defensive and counter-cyclical: discount retail is relatively insulated from both the Fed and a weakening consumer — it can benefit from the latter. The risk isn't rates; it's sentiment and momentum, which remain against the stock for now.
A fundamentally improving discount retailer trading near 52-week lows with ~60% analyst-implied upside — the deep contrarian value setup. But it has the lowest win rate on the list, poor momentum, and freshly trimmed targets; size the falling-knife risk deliberately.
The three setups, side by side
| Ticker | Frequency | Profit Factor | Ann. Return | Annual Win % | Catalyst |
|---|---|---|---|---|---|
| WINGWingstop | 81.82% | 4.49 | 135.7% | 80% | Earnings Jul 29 |
| IQVIQVIA Holdings | 84.62% | 11.51 | 75% | 83.33% | Earnings ~Jul 28 |
| OLLIOllie's Bargain Outlet | 81.82% | 4.47 | 79.68% | 70% | Earnings ~Aug 27 |
The Big Picture
Three setups, one idea: play the consumer whipsaw and the AI-in-healthcare theme, well away from the crowded mega-cap-tech trade.
Notice how the macro reads across them. A softer consumer and cooling inflation are a tailwind for WING's traffic and a structural positive for OLLI's trade-down model, while IQV mostly sidesteps the consumer. If last week's disinflation holds, the consumer names get their relief; if the oil rebound wins, OLLI's counter-cyclical model and IQV's defensiveness are the hedges. That spread is the point — a watchlist with a way to work whichever way the CPI-versus-oil tug-of-war breaks.
The goal is never to predict the week perfectly. Seasonality gives you the roadmap; the data and earnings calendars give you the catalysts; the macro backdrop tells you which risks to size carefully. From there: watch the price action, respect your stops, and refuse to let emotion decide.
Sign Up to View Full Trade Details →Super Seasonal Trade Desk
